NCT07154914View on ClinicalTrials.gov

A Novel Insight Into CRPC Progression and Immune: Evidence From Single-cell Spatial Transcriptome Multi-omics

Not yet recruitingOBSERVATIONAL

Enrollment

396

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2026

Conditions

Metastatic Hormone-Sensitive Prostate Cance

Interventions

DRUG

Abiraterone + ADT

Patients receiving androgen deprivation therapy (ADT) combined with abiraterone. Abiraterone is a CYP17A1 inhibitor used in combination with prednisone and ADT for metastatic hormone-sensitive prostate cancer (mHSPC). This combination is given in real-world practice according to clinical guidelines.

All Listed Sponsors

lead

Anhui Medical University

OTHER

NCT07154914 - A Novel Insight Into CRPC Progression and Immune: Evidence From Single-cell Spatial Transcriptome Multi-omics | Biotech Hunter | Biotech Hunter